A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)
NCT06433778 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34
Last updated 2026-03-11
Summary
This study is a retrospective chart review study and will collect data on real world use of vonicog alfa (Recombinant Von Willebrand Factor \[rVWF\]). Von Willebrand disease (VWD) is the most common inherited bleeding disorder. rVWF is approved in Europe and UK to treat bleeding and to treat and prevent bleeding during surgeries in adults in 2018.
This study will review and collect information on the treatment and bleed prevention of adult persons with inherited VWD with rVWF in UK. These data were already collected as a part of the routine care.
The main aims of this study are to describe the use of rVWF in on-demand treatment of bleeding and the prevention of treatment and treatment of bleeding during surgeries. Other aims are to describe bleedings and their treatment as well as any surgeries before and after first treatment with rVWF and to gather information on the use of healthcare resources (such as hospital visits, emergency room visits, etc.).
Conditions
- Von Willebrand Disease (VWD)
Interventions
- OTHER
-
No Intervention
This is a non-interventional study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Study Director · Takeda
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-16
- Primary Completion
- 2023-10-30
- Completion
- 2023-10-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
NCT02283268 ·Status: COMPLETED ·Phase: PHASE3
-
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
NCT04053699 ·Status: COMPLETED
-
A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi
NCT05265078 ·Status: COMPLETED
-
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
NCT07129343 ·Status: RECRUITING ·Phase: PHASE3
-
Optivate in People With Von Willebrand Disease Undergoing Surgery
NCT00404300 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
NCT00555555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)
NCT00630448 ·Status: WITHDRAWN
-
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
NCT00168090 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Voncento® in Subjects With Von Willebrand Disease
NCT02552576 ·Status: COMPLETED ·Phase: PHASE4
-
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
NCT04657887 ·Status: COMPLETED
-
Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)
NCT02466789 ·Status: COMPLETED
-
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
NCT00004667 ·Status: COMPLETED ·Phase: PHASE1
-
Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery
NCT01365546 ·Status: COMPLETED ·Phase: PHASE3
-
Type 3 Von Willebrand International Registries Inhibitor Prospective Study
NCT02460458 ·Status: COMPLETED
-
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease
NCT00816660 ·Status: COMPLETED ·Phase: PHASE1
-
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
NCT02792205 ·Status: COMPLETED
-
Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia
NCT01439971 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
NCT05487976 ·Status: UNKNOWN ·Phase: PHASE3
-
Minimize Menorrhagia in Women With Von Willebrand Disease
NCT02606045 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
NCT03695978 ·Status: RECRUITING
-
BT200 in Hereditary Bleeding Disorders
NCT04677803 ·Status: COMPLETED ·Phase: PHASE2
-
Real-life Data of Constitutional Von Willebrand Disease in Western France
NCT04887324 ·Status: COMPLETED
-
Recombinant vWF Concentrate and ECMO
NCT06118372 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
NCT00713648 ·Status: COMPLETED ·Phase: PHASE3
-
Von Willebrand Factor in Pregnancy (VIP) Study
NCT04146376 ·Status: RECRUITING